Telmisartan Drug Profile
What is Telmisartan?
Telmisartan is an oral medication belonging to a class of drugs called angiotensin receptor blockers (ARBs). It is primarily prescribed to treat high blood pressure (hypertension) and to reduce the risk of cardiovascular events in certain high-risk patients. This medication works by blocking specific receptors in the body that cause blood vessels to narrow.
Uses
Telmisartan is approved for several important cardiovascular conditions:
- High blood pressure (hypertension): Used as a first-line treatment to lower blood pressure in adults, either alone or in combination with other blood pressure medications
- Cardiovascular risk reduction: Prescribed for patients 55 years and older who are at high risk of heart attack, stroke, or cardiovascular death but cannot take ACE inhibitors
- Diabetic nephropathy: Helps protect kidney function in patients with type 2 diabetes who have protein in their urine
- Heart failure: Sometimes used as an alternative to ACE inhibitors in patients who cannot tolerate those medications
How it works
Telmisartan blocks angiotensin II receptors in blood vessel walls and other tissues. Angiotensin II is a hormone that causes blood vessels to constrict and promotes sodium retention, both of which increase blood pressure. By blocking these receptors, telmisartan allows blood vessels to relax and widen, reducing blood pressure and decreasing the workload on the heart.
Side effects
Common side effects include:
- Dizziness or lightheadedness
- Upper respiratory tract infections
- Back pain
- Diarrhea
- Fatigue
- Sinus congestion
- Muscle pain
- Nausea
Serious side effects requiring immediate medical attention:
- Severe drop in blood pressure causing fainting
- Signs of kidney problems (decreased urination, swelling, unusual fatigue)
- High potassium levels (irregular heartbeat, muscle weakness)
- Severe allergic reactions (swelling of face, lips, tongue, or throat)
- Liver problems (yellowing of skin or eyes, dark urine, severe stomach pain)
Warnings and precautions
- Pregnancy: Telmisartan can cause serious harm or death to developing babies and should not be used during pregnancy, especially in the second and third trimesters
- Kidney disease: Patients with severe kidney disease or those on dialysis should use this medication with extreme caution and require close monitoring
- Liver impairment: Dose adjustments may be necessary for patients with liver problems, as the medication is processed by the liver
- Dehydration: Patients who are dehydrated or have low blood volume are at increased risk of experiencing dangerous drops in blood pressure
- Heart conditions: Those with severe heart failure or aortic stenosis should be monitored closely when starting treatment
Interactions
- Potassium supplements and salt substitutes: Can increase potassium levels to dangerous amounts when combined with telmisartan
- Lithium: Telmisartan may increase lithium levels in the blood, potentially leading to lithium toxicity
- Nonsteroidal anti-inflammatory drugs (NSAIDs): May reduce the blood pressure-lowering effects and increase risk of kidney problems
- Diuretics: Combination may cause excessive blood pressure reduction, especially when starting treatment
- Other blood pressure medications: Additive effects may cause blood pressure to drop too low
- Digoxin: Telmisartan may slightly increase digoxin levels, requiring monitoring
- Warfarin: May slightly increase anticoagulant effects, requiring more frequent monitoring of blood clotting times
- ACE inhibitors: Combination increases risk of kidney problems and high potassium levels
Check interactions with the GMJ Interaction Checker
Dosage
For hypertension, the typical starting dose is 40 mg once daily, which may be increased to 80 mg once daily if needed. For cardiovascular risk reduction, the usual dose is 80 mg once daily. Telmisartan can be taken with or without food, and doses should be taken at the same time each day for best results. Patients with liver impairment may require lower starting doses. All dosage decisions should be made by a healthcare provider based on individual patient factors and response to treatment.
Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.
Cite this page
GMJ News Desk. "Telmisartan." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/telmisartan/
This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).Was this article helpful?


